Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0Y6NL
|
|||
| Former ID |
DIB016788
|
|||
| Drug Name |
Arepanrix
|
|||
| Synonyms |
H1N1 pandemic influenza vaccine (AS03 adjuvanted) 2, GlaxoSmithKline; H1N1 pandemic influenza vaccine2 (AS03 adjuvanted), GSK
Click to Show/Hide
|
|||
| Drug Type |
Vaccine
|
|||
| Indication | Influenza virus infection [ICD-11: 1E30-1E32] | Approved | [1], [2] | |
| Company |
GlaxoSmithKline plc
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Cell mediated immunity response (CMIR) | Target Info | . | [1], [3] |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015 | |||
| REF 2 | ClinicalTrials.gov (NCT01114620) Study of GSK Biologicals' Influenza Vaccine Arepanrix in Japanese Adults 65 Years of Age or Older. U.S. National Institutes of Health. | |||
| REF 3 | Comparison of Pandemrix and Arepanrix, two pH1N1 AS03-adjuvanted vaccines differentially associated with narcolepsy development. Brain Behav Immun. 2015 Jul;47:44-57. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.